Macular Degeneration News and Research

Latest Macular Degeneration News and Research

XOMA expands anti-inflammatory antibody intellectual property portfolio

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Patent and Trademark Office has issued two new patents that significantly expand the company's intellectual property portfolio relating to its anti-inflammatory antibody, XOMA 052, that targets interleukin-1 beta (IL-1 beta).

13 Apr 2010

Implanting blue light-filtering IOLs during cataract surgery may help preserve retina health

Implanting blue light-filtering intraocular lenses during cataract surgery helps maintain visual function and may preserve the health of the retina, specifically in disease states such as age-related macular degeneration, according to a comprehensive review published in the May/June 2010 edition of Survey of Ophthalmology.

13 Apr 2010

Tufts Medical Center researchers discover new biological pathway for advanced AMD

Researchers at Tufts Medical Center and collaborators discovered a new biological pathway for advanced age-related macular degeneration that implicates a role of the hepatic lipase gene, LIPC. This discovery will improve understanding of the disease by providing researchers another developmental pathway to explore for prevention and treatment.

13 Apr 2010

Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that researchers from the Mayo Clinic will be presenting data on the use of XOMA's high-affinity antibody to interleukin-1 beta (IL-1 beta), XOMA 052, in myeloma at the 101st Annual Meeting of the American Association of Cancer Research (AACR).

9 Apr 2010

Secretary of Health announces five health research grants to improve health of Pennsylvanians

Secretary of Health Everette James today announced five health research grants totaling approximately $20 million will be awarded from Pennsylvania's share of the national tobacco settlement for 2009-2010.

8 Apr 2010

Oraya Therapeutics' IRay stereotactic radiotherapy system granted European CE Mark approval

Oraya Therapeutics, Inc. announces today that a leading European notified body has granted approval to designate the CE mark to Oraya's IRayTM stereotactic radiotherapy system. Under development since 2007, the IRay is designed specifically to treat diseases of the eye, and the technology enables precise delivery of low energy X-rays for the treatment of wet age-related macular degeneration (AMD).

8 Apr 2010

Why is the genome project not yielding results faster?

As the genome projects reaches the 10 year landmark scientists are defending it. While the sequencing of the 3 billion letters in the human DNA took a long time the first draft of the human genome was presented ten years ago. Today it is possible to have your individual DNA mapped in a day and at the low cost of $5,000.

5 Apr 2010

RXi Pharmaceuticals reports net loss of 28% for 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported financial results for the fourth quarter and year ended December 31, 2009.

31 Mar 2010

Researcher explores the use of Chinese wolfberries to improve vision deficiencies

A Kansas State University researcher is exploring the use of Chinese wolfberries to improve vision deficiencies that are common for type-2 diabetics.

31 Mar 2010

BVA unveils wide-view neurostimulator concept, prototype bionic eye

Bionic Vision Australia today unveils their wide-view neurostimulator concept - a bionic eye that will be implanted into Australia's first recipient of the technology.

31 Mar 2010

READ 3 study for DME begins enrolling participants

A Phase II clinical trial for a promising treatment for diabetic eye disease has begun enrolling participants.

27 Mar 2010

Formatech selects Tracon Pharmaceuticals’ TRC102 inhibitor as next Fillanthropy Program candidate

Today, Formatech, Inc. announces the selection of Tracon Pharmaceuticals’ TRC102 clinical product as the next Fillanthropy™ Program candidate. Under this program, Formatech donates the services required to aseptically fill and finish one lot of the drug candidate to support Tracon’s upcoming clinical trials.

22 Mar 2010

Study shows that steroids target hemangioma stem cells

Hemangiomas -- strawberry-like birthmarks that commonly develop in early infancy - are generally harmless, but up to 10 percent cause tissue distortion or destruction and sometimes obstruction of vision or breathing. Since the 1960s, problematic hemangiomas have been treated with corticosteroids such as dexamethasone or prednisone.

19 Mar 2010

ISCO commences second phase of testing RPE derived from parthenogenetic stem cells

International Stem Cell Corporation, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine (UCI), is starting a second phase of essential pre-clinical experiments to test retinal pigment epithelium derived from parthenogenetic stem cells. Follow on pre-clinical experiments will be conducted to rescue vision in disease models.

18 Mar 2010

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

Manitobans with wet age-related macular degeneration (AMD) received a dose of good news. The Manitoba government announced that Lucentis (ranibizumab injection) will soon be funded through a centralized vision program, effective June 1, 2010.

18 Mar 2010

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD).

17 Mar 2010

Reversal of aging in normal human cells

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced the publication of a scientific paper titled “Spontaneous Reversal of Developmental Aging in Normal Human Cells Following Transcriptional Reprogramming.”

17 Mar 2010

OVD issue highlights prevalence of eye problems in general population

In the latest issue of Optometry & Vision Development (OVD), Dr. Dominick Maino, editor of OVD, notes that: "In 2010 there are 9 million people with lazy eye and 18 million individuals with eye-turns

17 Mar 2010

Promedior raises $12M in Series C financing

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.

16 Mar 2010

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).

15 Mar 2010

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

XOMA expands anti-inflammatory antibody intellectual property portfolio

Implanting blue light-filtering IOLs during cataract surgery may help preserve retina health

Tufts Medical Center researchers discover new biological pathway for advanced AMD

Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting

Secretary of Health announces five health research grants to improve health of Pennsylvanians

Oraya Therapeutics' IRay stereotactic radiotherapy system granted European CE Mark approval

Why is the genome project not yielding results faster?

RXi Pharmaceuticals reports net loss of 28% for 2009

Researcher explores the use of Chinese wolfberries to improve vision deficiencies

BVA unveils wide-view neurostimulator concept, prototype bionic eye

READ 3 study for DME begins enrolling participants

Formatech selects Tracon Pharmaceuticals’ TRC102 inhibitor as next Fillanthropy Program candidate

Study shows that steroids target hemangioma stem cells

ISCO commences second phase of testing RPE derived from parthenogenetic stem cells

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Reversal of aging in normal human cells

OVD issue highlights prevalence of eye problems in general population

Promedior raises $12M in Series C financing

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in